Kymera Therapeutics (KYMR) announced that Gilead Sciences has exercised its option to license KT-200, a first-in-class oral CDK2 molecular glue degrader discovered by Kymera. The move triggers a $45 million milestone payment to Kymera and advances KT-200 toward IND-enabling studies for planned 2027 clinical filing.
A New Approach to Targeting Cancer
KT-200 represents a novel therapeutic strategy that degrades CDK2, a key driver of tumor growth in CCNE1-amplified and overexpressed cancers, rather than merely inhibiting its function. This selective degradation could reduce off-target effects common with traditional CDK inhibitors and offer a safer, more precise treatment option for cancers such as advanced breast cancer, where current therapies remain limited.
In preclinical studies, KT-200 demonstrated low-nanomolar CDK2 degradation, strong activity in CCNE1-amplified cell lines and tumor models, brain-penetrant potential, and a favorable safety profile.
Collaboration and Financial Terms
Under the collaboration agreement, Kymera is eligible for up to $750 million in total milestone payments, including the $45 million triggered by this option exercise. To date, the company has received $85 million in upfront and option payments. Kymera will also earn tiered royalties ranging from high single-digit to mid-teen percentages on future net sales. Gilead now holds global rights to develop, manufacture, and commercialize KT-200 and other molecules arising from the partnership.
CEO's Perspective
"We are excited to have reached this key milestone in our strategic collaboration with Gilead, underscoring our commitment to advancing a new generation of medicines for patients through our innovative discovered engine," said Nello Mainolfi, Ph.D., Founder, President and CEO of Kymera Therapeutics. He added that KT-200 is expected to be the first molecular glue discovery by Kymera to enter the clinic, highlighting the company's progress in applying targeted protein degradation to difficult-to-treat cancers.
KYMR has traded between $19.44 and $103.00 over the past year. The stock closed yesterday's trading at $87.13, up 2.39%. In pre-market trading, the stock is at $89.50, up 2.72%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.